📇 Rhumatologue · MULHOUSE CEDEX 1 · (68) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
20 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
110.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
POUPONNIÈRE L'ERMITAGE
51 BD GAMBETTA BP 11105, 68052 MULHOUSE CEDEX 1
CABINET DU DR Giulia ROMEO
4 RUE DU 25 NOVEMBRE, 68350 DIDENHEIM
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
CABINET DU DR SYLVIE LEWANDOWSKI
4 RUE DU 25 NOVEMBRE, 68350 DIDENHEIM
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
International journal of molecular medicine · 2016
RMD open · 2023
Objectives In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients. Methods We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019. Results A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab. Conclusion In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of translational medicine · 2026 · Journal Article
Wang L, Qi H, Zhang Y, Wei G, et al.
Journal of the American Medical Informatics Association : JAMIA · 2026 · Journal Article
E T, Li X, Liang J, Ma J, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2025 · Journal Article
G A, C G, C J M, B L, et al.
Rheumatology (Oxford, England) · 2024 · Journal Article
Wang L, Chen S, Zhang H, Wei G, et al.
Rheumatology advances in practice · 2023 · Journal Article
Ebrahimiarjestan M, Yang L, E E, Wang T, et al.
BMC medical education · 2023 · Journal Article
Houpert R, Almont T, Mésenge C, Kleinebreil L, et al.
Heliyon · 2023 · Journal Article
Zheng Y, Deng J, Wang G, Zhang X, et al.
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2020 · Journal Article
Wang RH, Xu K, Li L, Wu ZF, et al.
Zhongguo gu shang = China journal of orthopaedics and traumatology · 2020 · Journal Article
Yu QB, E ZK, Xin HW, Zhang YS, et al.
The Pan African medical journal · 2016 · Journal Article
Martinetti AF, Franklin R, Lalao RR, Judicael HN, et al.
International journal of molecular medicine · 2016 · Journal Article
E LL, Xu WH, Feng L, Liu Y, et al.
Zhonghua nei ke za zhi · 2007 · English Abstract
Li JZ, Liu Y, E J, Huang HC, et al.
Chinese medical journal · 1999 · Journal Article
Zhang Y, Geng H, Zhao M, Zou W, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Journal of orthopaedic case reports · 2016 · Case Reports
Ay GR, D SR, T C, C K, et al.
AAS open research · 2021 · Journal Article
Nyangiri OA, Edwige SA, Koffi M, Mewamba E, et al.
Zhongguo shi yan xue ye xue za zhi · 2019 · Journal Article
Liu YF, He HQ, Ding YL, Wu SY, et al.
AAS open research · 2021 · Journal Article
Nyangiri OA, Edwige SA, Koffi M, Mewamba E, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026 · Consensus Statement
Fusaro M, Chandran M, Nickolas T, Ferrari S, et al.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry · 2025 · Journal Article
Ebrahimiarjestan M, O'sullivan M, Brennan A, E E, et al.